(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
4d Molecular Therapeutics's earnings in 2025 is -$160,868,000.On average, 6 Wall Street analysts forecast FDMT's earnings for 2025 to be -$157,580,982, with the lowest FDMT earnings forecast at -$174,097,050, and the highest FDMT earnings forecast at -$141,685,365. On average, 5 Wall Street analysts forecast FDMT's earnings for 2026 to be -$173,911,841, with the lowest FDMT earnings forecast at -$209,286,880, and the highest FDMT earnings forecast at -$136,592,101.
In 2027, FDMT is forecast to generate -$166,457,153 in earnings, with the lowest earnings forecast at -$200,026,398 and the highest earnings forecast at -$132,887,908.